Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5253545 | 0.98 | LTA4H (0.56) | LTA4HRAB9ANAMPTL3MBTL1PTPN1 | |
| SCHEMBL1993655 | 0.93 | L3MBTL1 (0.58) | LTA4HRAB9ANAMPTL3MBTL1PTPN1 | |
| SCHEMBL7143886 | 0.92 | RAB9A (0.51) | LTA4HRAB9ANAMPTL3MBTL1PTPN1 | |
| SCHEMBL6203734 | 0.86 | ALDH1A1 (0.55) | RAB9AL3MBTL1CYP3A4NPC1MEN1 | |
| SCHEMBL6201900 | 0.86 | RAB9A (0.59) | RAB9AL3MBTL1PTPN1NPC1MAPK1 | |
| SCHEMBL7996829 | 0.85 | HTR7 (0.51) | LTA4HRAB9ANAMPTL3MBTL1PTPN1 | |
| SCHEMBL6775249 | 0.83 | NPC1 (0.62) | RAB9AL3MBTL1PTPN1CYP3A4NPC1 | |
| SCHEMBL6282286 | 0.82 | PTPN1 (0.56) | NAMPTPTPN1MAPTPLOD2CES2 | |
| SCHEMBL4102938 | 0.81 | L3MBTL1 (0.68) | RAB9ANAMPTL3MBTL1CYP3A4MAPK14 | |
| SCHEMBL7433779 | 0.81 | LMNA (0.58) | RAB9AL3MBTL1NPC1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151256-B | Novel compounds for the treatment of diseases associated with DUX4 expression | 因维戈疗法有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7964534-B2 | Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes | TRIAD LIQUIDATING COMPANY, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-5296479-A | Treating physiological or drug-induced psychosis or dyskinesia | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-22 | — | — | US | disclosed |
| US-5266572-A | Antipsychotic 1-cycloalkylpiperidines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| US-5243048-A | Treatment of drug-induced or physiological psychosis or dyskinesia; side effect reduction | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0531901-A2 | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-5116846-A | N-ARALKYL PIPERIDINE DERIVATIVES AS PSYCHOTROPIC DRUGS | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-05-26 | — | — | US | disclosed |
| US-5109002-A | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0449186-A2 | N-aralkyl piperidine derivatives as psychotropic drugs | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | LTA4H 3217/4885RAB9A 827/4885NAMPT 1562/4885 |
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | REN, FURIN, QTRT1 | LTA4H 3380/4885RAB9A 259/4885NAMPT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.